Navigation Links
Therapeutic DNA Vaccine Company Inovio Biomedical Reports Second Quarter 2008 Financial Results
Date:8/7/2008

ation of intangible assets, were $3.1 million and $5.5 million for the three and six months ended June 30, 2008, respectively, as compared to $2.3 million and $4.6 million for the three and six months ended June 30, 2007, respectively. The increase in general and administrative expenses for the three and six months ended June 30, 2008, compared to the same periods in 2007, was primarily due to an increase in outside consulting services and legal fees related to the negotiation and execution of the definitive merger agreement with VGX Pharmaceuticals, Inc., announced July 7, 2008.

Net Loss Attributable to Common Stockholders

The decrease in net loss attributable to common stockholders for the six months ended June 30, 2008, compared with the same period in 2007, resulted primarily from the increase in collaborative research and development revenue and the decrease in research and development operating expenses, as described above.

Capital Resources

We ended the second quarter of 2008 with cash and short-term investments of $8.1 million and working capital of $5.7 million, compared with $27.3 million in cash and short-term investments and $25.6 million in working capital as of December31, 2007. The decrease in working capital during the six months ended June 30, 2008, was primarily due to the reclassification of $12.5 million of auction rate security ("ARS") investments from short-term to non-current assets. The remaining decrease in working capital was primarily due to expenditures related to our research and development and clinical trial activities, as well as various general and administrative expenses related to consultants, legal, accounting and audit, corporate development, and investor relations activities.

With respect to the reclassification of ARS investments, we originally purchased six high-grade ARSs, issued primarily by municipalities, for approximately $13.6 million. In March 2008, our in
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Stiefel Laboratories Completes Acquisition of Barrier Therapeutics
2. Nektar Therapeutics Announces Second Quarter 2008 Results
3. Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
4. InteKrin Therapeutics Announces $20 Million Series C Financing
5. Transition Therapeutics Announces No Material Change
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on August 8
7. DIA/AAPS Co-Sponsored Conference to Examine the Immunogenicity of Therapeutic Proteins
8. Cell Therapeutics, Inc. Announces $12 Million Equity Line of Credit
9. Stiefel Laboratories, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period Relating to its Proposal to Acquire Barrier Therapeutics, Inc.
10. Neurotherapeutics presents special issue on new treatments for Alzheimers disease
11. Horizon Therapeutics Names Timothy P. Walbert as President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Therapeutic DNA Vaccine Company Inovio Biomedical Reports Second Quarter 2008 Financial Results 
(Date:11/24/2014)... NY (PRWEB) November 24, 2014 From embedded ... progressive world of fitness technology will take center stage at ... Digital Times at the 2015 International CES® , ... the Venetian, Level 2, Bellini 2004). The bond between fitness ... into being less about devices and more about the human ...
(Date:11/24/2014)... 2014 Volpara Solutions announced today ... the 100th Annual Meeting of the Radiology Society ... (RSNA Booth 1752 – South Hall). Volpara Solutions ... the rest of its innovative suite of quantitative ... enable personalized measurements of volumetric density, patient-specific dose, ...
(Date:11/24/2014)... Dallas, TX (PRWEB) November 24, 2014 ... ADP ribose polymerase (PARP) and is one of the ... genetically vulnerable to creating some types of melanoma, and ... but this also sometimes gives their malignancies a exclusive ... on PARP to fix their DNA and allow them ...
(Date:11/24/2014)... 24, 2014 Mental health issues ... They break up families, ruin careers, and generally ... for those that suffer,” says Hardy Nutritionals® ... showing that our specialized nutritional treatments can reverse ... on “Mind Over Matter”, the premiere episode of ...
(Date:11/24/2014)... 24, 2014 Gersowitz Libo & Korek, P.C., ... received national Tier recognition in the 2015 Edition of U.S. ... ranking signals a unique combination of quality law practice and ... receive this honor and especially grateful to our clients whose ... and ranking possible,” said Jeff S. Korek, senior partner at ...
Breaking Medicine News(10 mins):Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 2Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 3Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 4Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 2Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 2Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 4Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 2Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 3Health News:U.S. News-Best Lawyers “Best Law Firms” Names Gersowitz Libo & Korek P.C. a 2015 Tier 1 Ranking Firm 2
... Campaigners have announced that there is a lack of specialist ... to the Scottish Drugs Forum, in spite of the rise ... there are only 2 publicly funded centres specifically for cocaine ... Aberdeen and Edinburgh. 1-in-5 drug-related deaths in greater Glasgow area ...
... have identified the gene that may be responsible for glue ear ... is the major cause of hearing// impairment in children. This condition ... 50% of the kids less than one year old are affected ... bouts. Though the involvement of genes in otitis media was already ...
... of the Health Ministers of chikungunya-affected States will be oganised ... capital today//. ,The agenda is to come ... affected more than 1.3 million people in India. Chikungunya has ... Anbumani Ramadoss will chair the meeting of the Health Ministers ...
... Government plans to reform the unwieldy Pharmaceutical Benefits Scheme ... into making more new medicines available to more Australians. ... Gullotta said reports that Health Minister Tony Abbott is ... effectively are a welcome start to much-needed PBS reforms. ...
... Nine people, including three women and three kids, were killed ... consumed //rotten fish at a government-run relief camp in Chhattisgarh's ... sent late Monday to the relief camp in Injeram village ... ,"A group of 50 tribals brought rotten fish ...
... of Medicine, the Regenstrief Institute, Inc. and the Richard ... research regarding guidelines that control antibiotics and antibiotic resistance ... guide lines which have been laid down to control ... antibiotic resistance as well. , ,The researchers ...
Cached Medicine News:Health News:‘Evil’ Gene causing ‘glue ear’ in 2Health News:AMA Welcomes Government Plans to Reform PBS 2Health News:Efforts to Check Uncontrolled use of Antibiotics and Antibiotic Resistance 2
(Date:11/22/2014)... , Nov. 22, 2014  New data demonstrates that ... most common form of female sexual dysfunction, Hypoactive Sexual ... or driving performance in premenopausal women when taken at ... Society of North America,s (SMSNA) ... . SMSNA accepted this study ...
(Date:11/22/2014)... , Nov. 21, 2014 Statistics released from ... drunk driving increase astronomically during the holidays, beginning with ... many cities. The data, highlighted ... Systems as part of their annual Sober ... a picture of high-risk drinking and increased rates of ...
(Date:11/22/2014)... , Nov. 21, 2014 Many power ... the growing influence of patients in the biopharmaceutical ... interactions. Now, more than ever, understanding how to ... medical products is essential. According ... LLC, benchmarked companies spent about two-thirds of their ...
Breaking Medicine Technology:Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 2Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 3Alarming Stats Show Holiday Drinking an Issue for Many 2New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2
... Automate the Interface between Health Assessments for ... Customized Care Treatment Plans, AUBURN, Calif., Jan. ... the development of medical management software,applications through acuity ... three new clinical content programs, referred to as,the ...
... the Journal of the ... American Cancer Society, ... CTIC ; MTAX) announced today that results of a phase ... of radioimmunotherapy (RIT) to chemotherapy for previously,untreated patients with non-follicular ...
Cached Medicine Technology:TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY 2TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY 3Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent 2Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent 3Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent 4Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent 5
... The remote vision controls ... NP-3S chart projector from the ... the autorefraction measurements can be ... via wireless data transfer. The ...
... testing provides clinically beneficial information in ... Dark adaptometry is useful in the ... senile miosis, high myopia, vitamin-A deficiency, ... whole-field scotopic sensitivity has been shown ...
... 3000 is the most advanced visual ... accurate measurements of retinal and optic ... software available drives this powerful computer-controlled ... adjustable contrast pattern stimulation, rapid Ganzfeld ...
The STALIF stand-alone anterior lumbar fusion cage is the latest product development from Surgicraft. STALIF is the natural evolution of the Hartshill Horseshoe, which has over 10 years clinical suc...
Medicine Products: